Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?

[1]  C. Begley,et al.  Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG‐rHuMGDF , 1997, British journal of haematology.

[2]  R. Benjamin,et al.  Stimulation of Megakaryocyte and Platelet Production by a Single Dose of Recombinant Human Thrombopoietin in Patients with Cancer , 1997, Annals of Internal Medicine.

[3]  D. Kuter.  In vivo effects of Mpl ligand administration and emerging clinical applications for the Mpl ligands , 1997, Current opinion in hematology.

[4]  J. Rasko,et al.  Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. , 1997, Blood.

[5]  R. Figlin,et al.  Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. , 1997, The New England journal of medicine.

[6]  J T Arnold,et al.  A single injection of pegylated murine megakaryocyte growth and development factor (MGDF) into mice is sufficient to produce a profound stimulation of megakaryocyte frequency, size, and ploidization. , 1997, Blood.

[7]  M. Smetak,et al.  Effects of Recombinant Human Thrombopoietin Alone and in Combination with Erythropoietin and Early‐Acting Cytokines on Human Mobilized Purified CD34+ Progenitor Cells Cultured in Serum‐Depleted Medium , 1997, Stem cells.

[8]  J. Nichol.  Serum Levels of Thrombopoietin in Health and Disease , 1997 .

[9]  C. Begley,et al.  Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer , 1996, The Lancet.

[10]  Seghatchian Mj.  Megakaryocyte growth and development factor and platelet aggregation , 1996 .

[11]  S. Hanson,et al.  Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. , 1996, Blood.

[12]  G. Senaldi,et al.  Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. , 1996, Blood.

[13]  A. Farese,et al.  Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. , 1996, The Journal of clinical investigation.

[14]  A. Gurney,et al.  Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. , 1996, Blood.

[15]  S. Hanson,et al.  Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. , 1996, Blood.

[16]  J. Groopman,et al.  Modulation of megakaryocytopoiesis by thrombopoietin: the c-Mpl ligand. , 1995, Blood.

[17]  T. Boone,et al.  Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. , 1995, Blood.

[18]  Eaton Dl,et al.  Thrombopoietin and the humoral regulation of thrombocytopoiesis. , 1995 .

[19]  A. Gurney,et al.  Thrombocytopenia in c-mpl-deficient mice. , 1994, Science.

[20]  W. Vainchenker,et al.  Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. , 1993, Blood.